Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone Mineral Density Loss in Relapsing-remitting Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Matched Case-control Study.

International journal of preventive medicine·2026
Same author

Early Posttransplant Lymphoproliferative Disorder and Cryptosporidiosis After Liver Transplantation.

Case reports in medicine·2026
Same author

Cognitive Impairment and Quality of Life in AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study in Iranian Patients.

Neurology research international·2026
Same author

A Functional Shape Framework for the Detection of Multiple Sclerosis Using Optical Coherence Tomography Images.

Sensors (Basel, Switzerland)·2026
Same author

Long-Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real-World Longitudinal Study.

Health science reports·2026
Same author

Empowering women's health with miRNA-integrated nanochemical approaches: from reproductive health to cancer care.

RSC advances·2026

Related Experiment Video

Updated: Jan 4, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.8K

Rituximab associated necrosis: A case report.

Fereshteh Ashtari1, Atousa Hakamifard2, Amirali Hariri3

  • 1Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Multiple Sclerosis and Related Disorders
|November 2, 2019
PubMed
Summary

Rituximab treatment, a B-cell depleting therapy, may rarely cause mucosal necrosis. This case highlights oral complications, specifically palatal necrosis, in a patient with Devic's syndrome following rituximab administration.

Keywords:
Devic's syndromeNecrosisRituximab

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

Related Experiment Videos

Last Updated: Jan 4, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.8K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

Area of Science:

  • Immunology
  • Neurology
  • Oncology

Background:

  • Rituximab, a monoclonal antibody targeting CD20, is widely used for autoimmune diseases and cancers.
  • B-cell depletion is its primary mechanism of action.
  • Rare adverse events associated with rituximab therapy are increasingly reported.

Observation:

  • A patient with Devic's syndrome developed oral manifestations following rituximab treatment.
  • The patient presented with palatal mucosal necrosis.
  • This represents a rare complication of anti-CD20 therapy.

Findings:

  • The case report details the occurrence of palatal necrosis after rituximab administration.
  • This finding suggests a potential link between anti-CD20 antibodies and mucosal necrosis.
  • The iatrogenic effects of rituximab warrant further investigation.

Implications:

  • Clinicians should be aware of the potential for rituximab-associated mucosal necrosis.
  • Early recognition and management of this rare complication are crucial.
  • Further research is needed to understand the pathophysiology and incidence of this adverse event.